The extent and severity of disease drive decisions regarding induction and maintenance regimens.
Sponsoring Organization: American College of GastroenterologyBackground and Objective
The management of ulcerative colitis (UC) has changed since the last guideline was published in 2010. The recommendations in the current update are based on the quality of evidence using GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology.
What's Changed
New tests, including those based on serum drug levels and fecal calprotectin, as well as newer FDA-approved therapies, including budesonide, vedolizumab, and tofacitinib
Key Recommendations
Screen patients with UC for coexisting anxiety and depressive disorders, and when identified, provide patients with resources to address these conditions.
Treat patients with UC to achieve m…
Reviewing Author
DisclosuresConsultant/Advisory BoardAbbVie; UpToDate; Spherix Health; Samsung Bioepis
Grant/Research SupportCrohns and Colitis Foundation
Leadership Positions in Professional SocietiesAmerican College of Gastroenterology (Immediate Past President)
DisclosuresConsultant/Advisory BoardAbbVie; UpToDate; Spherix Health; Samsung Bioepis
Grant/Research SupportCrohns and Colitis Foundation
Leadership Positions in Professional SocietiesAmerican College of Gastroenterology (Immediate Past President)